Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine373 Zhejiang University101 First Affiliated Hospital of Zhejiang University100 AstraZeneca74 Zhejiang Cancer Hospital65
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Hangzhou

1819 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
GlaxoSmithKline
Phase 3
450
Shijiazhuang, Shanghai, Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2025-12-03
Recruiting
Pfizer
Phase 3
450
Beijing, Shenzhen, Changsha, Nanchang, Hangzhou, Shanghai
2025-12-02
Recruiting
Bristol-Myers Squibb
Phase 3
650
Beijing, Haidian District, Guangzhou, Shenzhen, Changsha, Nanjing, Tianjin, Hangzhou
2025-12-02
Recruiting
Qian Chu
Observational
500
Wuhan, Hangzhou
2025-12-01
Recruiting
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,544
Hangzhou
2025-12-01
Recruiting
Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia
NCT07263906Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
48
Hangzhou
2025-12-01
Recruiting
Sir Run Run Shaw Hospital
Not applicable
33
Hangzhou
2025-12-01
Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
NCT07305116Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
15
Hangzhou
2025-12-01
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
84
Beijing, Fuzhou, Nanchang, Jinan, Shanghai, Hangzhou
2025-12-01
Not yet open
A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
NCT07169175Amyotrophic Lateral Sclerosis (ALS)
DrugSNUG01
SineuGene Therapeutics Co., Ltd.
Phase 1/2
21
Beijing, Fuzhou, Hangzhou
2025-12-01
Not yet open
Women's Hospital School Of Medicine Zhejiang University
Phase 2
42
Hangzhou
2025-12-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
31
Hangzhou
2025-12-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
10
Hangzhou
2025-12-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
2,000
Hangzhou
2025-12-01
Recruiting
Zhejiang University
Phase 2
50
Hangzhou
2025-11-30
Recruiting
Zhejiang University
Phase 1
20
Hangzhou
2025-11-30
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
Changde, Guangzhou, Hangzhou, Jiangmen, Luoyang
2025-11-28
Recruiting
Novartis Pharmaceuticals
Phase 3
31
Hangzhou, Beijing
2025-11-27
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 2
78
Beijing, Guangzhou, Hangzhou, Nanchang
2025-11-26
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
25
Hangzhou
2025-11-25
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
25
Hangzhou
2025-11-25
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
25
Hangzhou
2025-11-25
Not yet open
Zhang Jianguo
Not applicable
86
Beijing, Wuhan, Nanjing, Dalian, Jinan, Shanghai, Tianjin, Hangzhou
2025-11-24
Recruiting
Eli Lilly and Company
Phase 2
400
Changsha, Hangzhou, Huzhou, Jinan, Shanghai, Shijiazhuang, Tianjin, Xiamen
2025-11-24
Recruiting
Longitudinal Follow-up and Health-Related Outcomes in Liver Transplant Recipients and Living Donors
NCT07301853Living Donor Liver Transplantation Recipients, Deceased Donor Liver Transplantation Recipients, Living Liver Donor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
9,999
Hangzhou
2025-11-24
Recruiting
Hoffmann-La Roche
Phase 3
900
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing
2025-11-24
Recruiting
Zhejiang Hospital
Not applicable
200
Hangzhou
2025-11-23
Recruiting
Huashan Hospital
Phase 4
426
Beijing, Liupanshui, Nayong, Shanghai, Hangzhou
2025-11-21
Recruiting
Effect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients
NCT07252102Liver Cirrhosis, Polyps of Colon, Gastrointestinal Dysfunction
Zhejiang University
Not applicable
450
Shenzhen, Hangzhou
2025-11-20
Not yet open
First People's Hospital of Hangzhou
Phase 4
240
Hangzhou
2025-11-20
Recruiting
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase 1/2
258
Hangzhou
2025-11-20
Active, closed
Bayer
Phase 2
60
Beijing, Guangzhou, Wuhan, Hangzhou
2025-11-19
Recruiting
Lu Chao
Not applicable
76
Hangzhou
2025-11-18
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
320
Hangzhou
2025-11-17
Recruiting
Sanofi
Observational
1,000
Beijing, Shenzhen, Changsha, Xi’an, Chengdu, Hangzhou, Ningbo, Chongqing
2025-11-17
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
400
Changchun, Tianjin, Hangzhou
2025-11-15
Recruiting
Zhejiang Cancer Hospital
Phase 3
292
Hangzhou
2025-11-15
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Early Phase 1
36
Hangzhou
2025-11-15
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
206
Hangzhou
2025-11-15
Recruiting
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
NCT07209813Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
DrugGKL-006
Beijing Gene Key Life Technology Co., Ltd
Phase 2
48
Beijing, Zhengzhou, Changsha, Nanjing, Nanchang, Hangzhou
2025-11-14
Recruiting
UCB Biopharma SRL
Phase 3
320
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Shenzhen
2025-11-14
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
464
Fuzhou, Harbin, Nanjing, Jinan, Tianjin, Hangzhou
2025-11-12
Recruiting
Shanghai Longwood Biopharmaceuticals Co., Ltd.
Phase 1/2
270
Hangzhou
2025-11-11
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Early Phase 1
6
Hangzhou
2025-11-10
Recruiting
AstraZeneca
Phase 1
40
Chengdu, Hangzhou, Nanjing, Shanghai, Wuhan, Xiamen
2025-11-10
Recruiting
Eli Lilly and Company
Phase 2
252
Changzhou, Chongqing, Fuzhou, Hangzhou, Kunming, Nanjing, Qingdao, Shenyang
2025-11-10
Recruiting
Gang Chen
Not applicable
170
Hangzhou
2025-11-10
Recruiting
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Harbin, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
Shanghai Synvida Biotechnology Co.,Ltd.
Phase 2
48
Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Neimeng, Shanghai, Tianjin
2025-11-04
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
12
Hangzhou
2025-11-03
Active, closed
Takeda
Phase 2
207
Wuhan, Xi'an, Shanghai, Kunming, Hangzhou
2025-11-03
Recruiting
Zhejiang Cancer Hospital
Phase 2
60
Hangzhou
2025-11-03
Recruiting
Eli Lilly and Company
Phase 2
222
Beijing, Chengdu, Chongqing, Hangzhou, Linhai, Ningbo, Shenzhen
2025-11-03
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
11,000
Hangzhou
2025-11-01
Recruiting
Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
NCT07359586Gastric Cancer, Hepatic Carcinoma, Pulmonary Carcinoma, Pancreatic Carcinoma
Zhejiang University
Observational
1,200
Hangzhou
2025-11-01
Active, closed
Chen Dajin
Observational
1,000
Hangzhou
2025-11-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
25
Hangzhou
2025-11-01
Recruiting
The Children's Hospital of Zhejiang University School of Medicine
Observational
1,000
Hangzhou
2025-11-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
120
Hangzhou
2025-11-01
Recruiting
Takeda
Observational
200
Hefei, Beijing, Fuzhou, Hangzhou, Shantou, Shenzhen, Shijiazhuang, Harbin
2025-11-01
Recruiting
Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Outcomes of Severe Mental Disorders
NCT07479758Major Depressive Disorder (MDD), Schizophrenia, Bipolar Disorder, Severe Mental Disorders
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
320
Hangzhou
2025-11-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
200
Hangzhou
2025-11
Recruiting
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
NCT07233642Systemic Lupus Erythematosus
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
18
Hangzhou
2025-11
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
238
Hangzhou
2025-10-31
Recruiting
AstraZeneca
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-10-31
Recruiting
Dynamic Airway Resistance & ML: Guide Sputum Suction in Ventilated Patients
NCT07375667Mechanical Ventilation Pressure High, Ventilator-Associated Pneumonia (VAP), Respiratory Depression Neonatal
Affiliated Hospital of Nantong University
Not applicable
258
Bengbu, Beijing, Hangzhou
2025-10-30
Recruiting
Pfizer
Phase 2
200
Beijing, Guangzhou, Shijiazhuang, Shanghai, Tianjin, Hangzhou
2025-10-30
Recruiting
Auricular Stimulation for Functional Dyspepsia With Insomnia: Efficacy and Mechanisms
NCT07442734Functional Dyspepsia, Insomnia, Brain and Nervous System
The First Affiliated Hospital of Zhejiang Chinese Medical University
Not applicable
176
Hangzhou
2025-10-30
Recruiting
GlaxoSmithKline
Phase 2
363
Beijing, Chongqing, Dongguan, Guangzhou, Guilin, Hangzhou, Huizhou, Jiangmen
2025-10-30
Recruiting
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1
12
Beijing, Changchun, Guangzhou, Hangzhou, Suzhou, Wenzhou, Wuhan
2025-10-29
Recruiting
SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
NCT07162714Rectal Cancer, Radiation, AK112
DrugIvonescimab
Zhejiang Cancer Hospital
Phase 2
30
Hangzhou
2025-10-27
Not yet open
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2
184
Hangzhou, Shenyang
2025-10-27
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 2/3
360
Zhengzhou, Hangzhou
2025-10-24
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,096
Nanchang, Shenyang, Hangzhou, Tianjin
2025-10-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Hefei, Nanchang, Hangzhou, Beijing, Bengbu, Changsha, Chengdu, Guangzhou
2025-10-24
Recruiting
Zhejiang University
Not applicable
410
Beijing, Jinjiang, Hangzhou, Lishui, Taizhou
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-10-24
Recruiting
Eli Lilly and Company
Phase 2
531
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
1,630
Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan
2025-10-22
Active, closed
Zhejiang Cancer Hospital
Observational
10,000,000
Hangzhou
2025-10-22
Recruiting
Zhejiang University
Phase 2
70
Hangzhou
2025-10-21
Active, closed
BeiGene
Phase 4
16
Beijing, Guangzhou, Baoding, Yichang, Changsha, Hangzhou
2025-10-17
Recruiting
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2025-10-16
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
27
Hangzhou
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou
2025-10-15
Active, closed
Fertility Decision and Outcomes in Young Women With Breast Cancer
NCT07804745Breast Cancer - Female, Fertility
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
300
Changchun, Hangzhou
2025-10-15
Recruiting
Changhai Hospital
Not applicable
1,250
Baotou, Beijing, Hangzhou, Hunan, Lanzhou, Shandong, Shanghai, Yunnan
2025-10-13
Recruiting
A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
NCT07250386NSCLC (Advanced Non-small Cell Lung Cancer), Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
48
Hangzhou
2025-10-13
Recruiting
Zhejiang Cancer Hospital
Not applicable
9
Hangzhou
2025-10-12
Recruiting
Sir Run Run Shaw Hospital
Phase 2
52
Hangzhou
2025-10-09
Recruiting
Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD
NCT07385131Inflammatory Bowel Disease (IBD), CD - Crohn's Disease, UC - Ulcerative Colitis
DrugDexamethasone
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
300
Hangzhou
2025-10-08
Recruiting
Jichao Qin
Observational
400
Hangzhou
2025-10-07
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
60
Hangzhou
2025-10-07
Recruiting
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Phase 1
86
Hangzhou, Shanghai
2025-10-05
Recruiting
Electroacupuncture Treatment for Post-stroke Cognitive Impairment
NCT07208019Post-Stroke Cognitive Impairment (PSCI)
Ruijie Ma
Not applicable
340
Hangzhou
2025-10-05
Recruiting
The First Affiliated Hospital of Soochow University
Not applicable
224
Suzhou, Xuzhou, Hangzhou
2025-10-01
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
200
Hangzhou
2025-10-01
Recruiting
Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.
NCT07329686Herpes Simplex Keratitis, Corneal Neovascularization
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
100
Hangzhou
2025-10-01
Not yet open
Study on Safety and Efficacy of UCB-MNCs for Chronic Radiation Enteritis
NCT07175207Chronic Radiation Induced Intestinal Injury, Chronic Radiation Enteritis
Zhejiang Cancer Hospital
Early Phase 1
10
Hangzhou
2025-10-01
Recruiting
Correlation Study of Atrophic Gastritis and Dyspepsia Symptoms
NCT07250308Functional Dyspepsia, Chronic Atrophic Gastritis (CAG)
The Third Affiliated hospital of Zhejiang Chinese Medical University
Observational
315
Hangzhou
2025-10-01
Not yet open
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
269
Hangzhou
2025-10-01
Not yet open
Yanbing Li
Observational
594
Hangzhou, Baoding, Beijing, Shanghai, Xi'an
2025-10-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
30
Hangzhou
2025-10-01
Recruiting
Eli Lilly and Company
Phase 3
1,000
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Lanzhou, Nanjing
2025-09-30
Recruiting
Zhejiang Provincial People's Hospital
Phase 1/2
10
Hangzhou
2025-09-30
Recruiting
RAINBOW-ICH Trial of AI Guided Minimally Invasive Neurosurgery for ICH
NCT07205263Basal Ganglia Hemorrhage, Intraventricular Hemorrhage, Brainstem Stroke, Intracranial Hemorrhage, Spontaneous
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,000
Hangzhou
2025-09-30
Recruiting
Vebreltinib for Advanced or Metastatic CCS
NCT07153887Clear Cell Sarcoma (CCS)
DrugVebreltinib
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
30
Hangzhou
2025-09-30
Active, closed
Cascade Pharmaceuticals, Inc
Phase 2
120
Fuzhou, Xiamen, Suzhou, Shanghai, Hangzhou, Wenzhou
2025-09-30
Recruiting
Immune Profiling of Refractory cSLE Exposed to CD3×CD19 BiTE
NCT07352332Childhood-onset Systemic Lupus Erythematosus
The Children's Hospital of Zhejiang University School of Medicine
Observational
6
Hangzhou
2025-09-30
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
330
Hangzhou
2025-09-30
Recruiting
A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
NCT07198867Acute Myeloid Leukemia (AML), CAR-T Cell Therapy
First Affiliated Hospital of Zhejiang University
Phase 1
20
Hangzhou
2025-09-30
Recruiting
Daiichi Sankyo
Phase 3
710
Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning
2025-09-30
Not yet open
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
150
Hangzhou
2025-09-26
Recruiting
Sanofi
Phase 3
124
Beijing, Chengdu, Hangzhou, Jiazhuang, Taiyuan, Wuhan, Yantai
2025-09-26
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
14
Hangzhou
2025-09-26
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
122
Hangzhou
2025-09-25
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
120
Hangzhou
2025-09-23
Recruiting
Sanofi
Phase 4
218
Chengdu, Guangzhou, Hangzhou, Harbin, Ningbo, Xiamen
2025-09-22
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Harbin, Shanghai, Hangzhou
2025-09-22
Active, closed
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
NCT07247383Marginal Zone Lymphoma of Ocular Adnexal, Marginal Zone Lymphoma(MZL)
DrugsOrelabrutinib·Rituximab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
39
Hangzhou
2025-09-19
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
1,384
Hangzhou
2025-09-18
Recruiting
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
NCT07172204Intensive Chemotherapy Unfit, Newly Diagnosed Acute Myeloid Leukemia (AML), Age ≥60
First Affiliated Hospital of Zhejiang University
Phase 2
25
Beijing, Shenzhen, Suzhou, Nanchang, Hangzhou
2025-09-16
Recruiting
Sanofi
Phase 3
942
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin
2025-09-16
Recruiting
Women's Hospital School Of Medicine Zhejiang University
Observational
1,600
Hangzhou
2025-09-16
Not yet open
Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer
NCT07188116Breast Cancer, Radiation Pneumonia, COVID-19
Zhejiang Hospital
Observational
200
Hangzhou
2025-09-15
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
414
Beijing, Chengdu, Guangzhou, Hangzhou, Luoyang, Macau, Nanchang, Shanghai
2025-09-13
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
120
Hangzhou
2025-09-12
Recruiting
Yifan Wang
Phase 1/2
20
Hangzhou
2025-09-11
Recruiting
Yinghua Xu
Phase 1/2
20
Hangzhou
2025-09-11
Recruiting
Pfizer
Phase 3
140
Beijing, Guangzhou, Changsha, Shanghai, Chengdu, Hangzhou
2025-09-10
Recruiting
Zhejiang Cancer Hospital
Observational
3
Hangzhou
2025-09-10
Recruiting
Bristol-Myers Squibb
Phase 2
182
Beijing, Xiamen, Nanning, Nanchang, Jinan, Linyi, Hangzhou, Linhai
2025-09-09
Recruiting
Chipscreen Biosciences, Ltd.
Phase 1/2
220
Beijing, Chengde, Shijiazhuang, Shiyan, Jinan, Taiyuan, Xi’an, Hangzhou
2025-09-08
Not yet open
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT07159906Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
DrugsHomoharringtonine·Lisaftoclax·Prednisone·Rituximab
First Affiliated Hospital of Zhejiang University
Phase 1/2
62
Hangzhou
2025-09-08
Recruiting
PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS
NCT07761533Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome)
Chaser Therapeutics, Inc.
Phase 1/2
29
Hangzhou
2025-09-08
Recruiting
Zhejiang University
Early Phase 1
50
Hangzhou
2025-09-05
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
50
Hangzhou
2025-09-05
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
90
Hangzhou
2025-09-01
Not yet open
Almazov National Medical Research Centre
Not applicable
200
Hangzhou
2025-09-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
96
Hangzhou
2025-09-01
Recruiting
AI-assisted Diagnosis of Malignant Brain Tumors
NCT07198256Gliomas, Brain Metastases, Adult, Lymphoma, Brain Tumor Adult
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
3,000
Hangzhou
2025-09-01
Recruiting
Deep Learning CAD Screening on Chest CT
NCT07181512Coronary Artery Disease, Coronary Artery Stenosis Stent
Yifan Guo
Observational
200
Hangzhou, Ningbo
2025-09-01
Recruiting
Microneedle Intra-Arterial Injection for Retinal Artery Occlusion
NCT07151755Central Retinal Artery Occlusion
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
24
Hangzhou
2025-09-01
Recruiting
Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease
NCT07068438Chronic Bronchitis, COPD (Chronic Obstructive Pulmonary Disease)
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
210
Hefei, Beijing, Changzhou, Suzhou, Wuxi, Xuzhou, Nanchang, Hangzhou
2025-09-01
Recruiting
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
NCT07184450Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
Chongqing Precision Biotech Co., Ltd
Phase 1
11
Hangzhou
2025-09-01
Recruiting
First People's Hospital of Hangzhou
Observational
39
Hangzhou
2025-09-01
Recruiting
Zhejiang Cancer Hospital
Phase 2
34
Hangzhou
2025-09-01
Recruiting
Women's Hospital School Of Medicine Zhejiang University
Phase 2
39
Hangzhou
2025-09-01
Not yet open
Liu Zhanghong
Early Phase 1
70
Hangzhou, Wenzhou
2025-09-01
Recruiting
Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
NCT07303023Nasopharyngeal Carcinoma (NPC)
Fudan University
Phase 3
462
Shanghai, Hangzhou, Chengdu, Chongqing
2025-09-01
Not yet open
The Resistant Starch Intervention for Cognitive Enhancement
NCT07152483Cognitive Impairment, Diet Interventions, Cognitive Decline, Genetic Risk Factors
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
70
Hangzhou
2025-09-01
Active, closed
Sir Run Run Shaw Hospital
Not applicable
5
Hangzhou
2025-09-01
Recruiting
Dexiong Han
Not applicable
228
Hangzhou
2025-09-01
Not yet open
Zhejiang Kanova Biopharmaceutical Co., LTD
Phase 2
120
Hangzhou
2025-08-31
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
200
Beijing, Hangzhou
2025-08-28
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
200
Shijiazhuang, Hangzhou
2025-08-28
Recruiting
China National Biotec Group Company Limited
Phase 1
76
Hangzhou
2025-08-28
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
Phrontline Biopharma
Phase 1
200
Zhengzhou, Wuhan, Hangzhou, Shanghai
2025-08-25
Recruiting
Mao Jianhua
Phase 2
30
Hangzhou
2025-08-25
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
153
Beijing, Guangzhou, Shanghai, Hangzhou
2025-08-21
Active, closed
Sir Run Run Shaw Hospital
Phase 2
29
Hangzhou
2025-08-20
Recruiting
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
NCT07183878Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes, High-Risk Myelodysplastic Syndromes
DrugsSemustine·Busulfan·Venclexta·Venetoclax
First Affiliated Hospital of Zhejiang University
Not applicable
138
Hangzhou
2025-08-20
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Yangzhou, Tianjin, Hangzhou, Huaian, Shanghai
2025-08-19
Recruiting
Dizal Pharmaceuticals
Phase 1/2
150
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan
2025-08-19
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
70
Hangzhou
2025-08-18
By invitation
Huabo Biopharm Co., Ltd.
Phase 2
60
Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin
2025-08-14
Recruiting
The Treatment Outcomes of Cesarean Scar Pregnancy
NCT07608094Cesarean Scar Pregnancy
Women's Hospital School Of Medicine Zhejiang University
Observational
82
Hangzhou
2025-08-13
Recruiting
BioNTech SE
Phase 1/2
1,438
Chongqing, Hangzhou, Tianjin, Wuhan
2025-08-12
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Hangzhou, Shanghai
2025-08-07
Recruiting
AstraZeneca
Phase 2
278
Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua
2025-08-06
Active, closed
First Affiliated Hospital of Zhejiang University
Phase 2
35
Hangzhou
2025-08-06
Recruiting
A Single-Center Clinical Study on the Efficacy and Safety of VISOR
NCT07071948Urolithiasis, Calcium Oxalate, Kidney Stone
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
20
Hangzhou
2025-08-06
Recruiting
Sanofi
Phase 3
723
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot
2025-08-06
Active, closed
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
Shanghai Henlius Biotech
Phase 2
24
Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing
2025-08-05
Recruiting
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
NCT07391839Hepatoma, Unresectable Hepatocellular Carcinoma (HCC)
Suzhou Mednovo Yi Medical Technology Co., Ltd.
Phase 1
40
Hefei, Fuzhou, Guangzhou, Nanjing, Jinan, Hangzhou, Henan, Shanghai
2025-08-04
Recruiting
Zhejiang University
Observational
5,000
Hangzhou, Jiaxing, Lishui
2025-08-03
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
400
Hangzhou
2025-08-01
Not yet open
Smartphone Multimodal Health Intervention for Neurological Enhancement (SHINE)
NCT07092371Cognitive Impairment, Dementia, Artificial Intelligence (AI), Stroke
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,036
Hangzhou
2025-08-01
Recruiting
Zhejiang University
Phase 1/2
20
Hangzhou
2025-08-01
Not yet open
29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
NCT07100236Primary Hepatocellular Carcinoma
Junjie Xu
Observational
350
Hefei, Chaoyang, Fuzhou, Guangzhou, Zhengzhou, Shanghai, Hangzhou, Wenzhou
2025-08-01
Active, closed
First Affiliated Hospital of Zhejiang University
Observational
40
Hangzhou
2025-08-01
Recruiting
Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival
NCT07813208Acute Lymphoblastic Leukemia, Pediatric
The Children's Hospital of Zhejiang University School of Medicine
Observational
500
Hangzhou
2025-08-01
Not yet open
China-Japan Friendship Hospital
Observational
100,000
Beijing, Shanghai, Changsha, Guiyang, Hangzhou, Henan, Qingdao, Shenyang
2025-08-01
Not yet open
The Impact of Culture in Cognitive Behavior Therapy (CBT) for Patients With Inflammatory Bowel Disease
NCT06713694Inflammatory Bowel Disease (IBD), Cognitive Behavior Therapy
Wang Zhen
Not applicable
40
Hangzhou
2025-08-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
200
Hangzhou
2025-08
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
31
Hangzhou
2025-08
Not yet open
TYK Medicines, Inc
Phase 1/2
48
Hangzhou
2025-08
Not yet open
TYK Medicines, Inc
Phase 1/2
48
Hangzhou
2025-08
Active, closed
Pfizer
Phase 3
208
Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Chengdu, Kunming, Hangzhou
2025-07-31
Not yet open
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xi’an, Hangzhou
2025-07-31
Recruiting
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
NCT07061535Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
DrugsTafolecimab·Ivonescimab·Etoposide·Sintilimab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
40
Changsha, Jinan, Hangzhou
2025-07-30
Recruiting
Zhejiang University
Not applicable
66
Hangzhou
2025-07-30
Recruiting
Beijing Tiantan Hospital
Phase 3
596
Beijing, Jiuquan, Shijiazhuang, Jiyuan, Lingbao, Nantong, Hangzhou
2025-07-30
Recruiting
Women's Hospital School Of Medicine Zhejiang University
Not applicable
1,074
Hangzhou
2025-07-30
Recruiting
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
NCT07022002Locally Advanced, Recurrent or Metastatic Malignancies
DrugSSGJ-705
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2
340
Hangzhou
2025-07-30
By invitation
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
50
Hangzhou
2025-07-28
Recruiting
AbbVie
Phase 3
120
Guangzhou, Zhengzhou, Changsha, Changchun, Shanghai, Hangzhou
2025-07-28
Not yet open
Individualized Location-based rTMS for Migraine Treatment: A Multicenter Clinical Study
NCT07086274Migraine, Transcranial Magnetic Stimulation Repetitive
First Affiliated Hospital of Zhejiang University
Not applicable
152
Hangzhou
2025-07-25
Recruiting
Fujian Akeylink Biotechnology Co., Ltd.
Phase 3
526
Hangzhou
2025-07-24
Recruiting
Pfizer
Phase 3
150
Beijing, Shenzhen, Changsha, Nanchang, Shanghai, Hangzhou
2025-07-24
Recruiting
Women's Hospital School Of Medicine Zhejiang University
Early Phase 1
250
Hangzhou
2025-07-21
Not yet open
Zhejiang Cancer Hospital
Phase 3
360
Hangzhou
2025-07-20
Recruiting
SuZhou Sinus Medical Technologies Co.,Ltd
Not applicable
124
Beijing, Hangzhou
2025-07-20
Not yet open
Xiangdong Cheng
Phase 3
470
Hangzhou
2025-07-20
By invitation
First People's Hospital of Hangzhou
Observational
171
Hangzhou
2025-07-20
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
320
Hangzhou
2025-07-20
Recruiting
BeOne Medicines
Phase 1
58
Beijing, Chongqing, Guangzhou, Wuhan, Changsha, Qingdao, Chengdu, Hangzhou
2025-07-19
Recruiting
Daiichi Sankyo
Phase 2
130
Beijing, Changchun, Guangzhou, Hangzhou, Nanchang, Nanjing, Nanning, Qingdao
2025-07-18
Recruiting
Clinical Efficacy and Mechanism of tDCS for Dysphagia in PD
NCT07153692Parkinson's Disease and Parkinsonism, Dysphagia
Wang Ping
Not applicable
58
Hangzhou
2025-07-17
Recruiting
AstraZeneca
Phase 2
100
Beijing, Changchun, Changzhi, Chengdu, Fuzhou, Hangzhou, Kunming, Qingdao
2025-07-17
Recruiting
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
594
Beijing, Shenzhen, Nanjing, Hangzhou
2025-07-16
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
106
Hangzhou
2025-07-16
Recruiting
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase 1
110
Hangzhou
2025-07-15
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
214
Hangzhou, Huzhou, Jinhua, Yueqing, Zhoushan
2025-07-14
Recruiting
The Dental Hospital of Zhejiang University School of Medicine
Observational
150
Hangzhou
2025-07-10
Recruiting
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
86
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou
2025-07-10
Not yet open
Qian Wenbin
Phase 1
27
Hangzhou
2025-07-08
Active, closed
Sanofi
Phase 2
105
Huizhou, Guangzhou, Nanjing, Suzhou, Wuxi, Shanghai, Hangzhou, Ningbo
2025-07-07
Active, closed
Shanghai Minwei Biotechnology Co., Ltd
Phase 1
54
Hangzhou
2025-07-07
Active, closed
Hoffmann-La Roche
Phase 4
60
Nanchang, Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot
2025-07-04
Recruiting
Sir Run Run Shaw Hospital
Phase 2
59
Hangzhou
2025-07-03
Recruiting
Shanghai Chest Hospital
Not applicable
186
Jinan, Shanghai, Hangzhou
2025-07-02
Recruiting
Smith & Nephew, Inc.
Not applicable
105
Guangzhou, Zhengzhou, Nanjing, Changchun, Hangzhou
2025-07-02
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Binhai, Changsha, Chengdu, Dongcheng, Fuzhou, Guangzhou, Haidian, Hangzhou
2025-07-02
Recruiting
18F-Pentixafor PET in Hematologic Malignancies
NCT07122674Hematological Malignancies
First Affiliated Hospital of Zhejiang University
Observational
100
Hangzhou
2025-07-01
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing
2025-07-01
Recruiting
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
NCT07068542Advanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma
DrugsSacituzumab tirumotecan·Tislelizumab
Zhejiang Provincial People's Hospital
Not applicable
94
Hangzhou
2025-07-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
10
Hangzhou
2025-07-01
Not yet open
Dexiong Han
Not applicable
207
Hangzhou
2025-07-01
Recruiting
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 1
40
Hangzhou, Shanghai
2025-07-01
Active, closed
VAP-Measured Lipid Subfractions and In-Stent Restenosis After PCI
NCT07533656In-Stent Restenosis, Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
3,600
Hangzhou
2025-07-01
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
500
Guangzhou, Shenyang, Chengdu, Hangzhou
2025-07-01
Not yet open
Wen-zhao ZHONG
Phase 2
134
Guangzhou, Changsha, Hangzhou
2025-07
Active, closed
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
72
Hangzhou
2025-06-30
Recruiting
Hangzhou Dinova EP Technology Co., Ltd
Not applicable
292
Hangzhou
2025-06-30
By invitation
Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)
NCT07023965Peripheral Arterial Disease(PAD), Arterial Occlusive Disease, Arteriosclerosis Obliterans, Thromboangiitis Obliterans
Beijing Northland Biotech. Co., Ltd.
Observational
542
Beijing, Chifeng, Dalian, Hangzhou, Xi'an
2025-06-30
Recruiting
Heronova Pharmaceuticals
Phase 1
32
Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha, Jinan, Hangzhou
2025-06-30
Recruiting
Effectiveness of DITM Versus IMT in COPD Patients
NCT06958666COPD (Chronic Obstructive Pulmonary Disease)
Sir Run Run Shaw Hospital
Not applicable
410
Hangzhou, Lishui, Taizhou
2025-06-30
By invitation
A Study on the Efficacy of Environmental Probiotics in Patients With Cat Hair Allergies
NCT07114133Cat Allergy (Disorder), Allergic Rhinitis, Allergic Asthma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2025-06-30
Recruiting
Zhejiang University
Not applicable
12
Hangzhou
2025-06-28
Recruiting
Zhejiang University
Phase 4
218
Hangzhou
2025-06-25
Active, closed
Incyte Corporation
Phase 1/2
32
Beijing, Chengdu, Chongoing, Guangzhou, Hangzhou, Shanghai, Tianjin, Wuhan
2025-06-25
Recruiting
A Study in Children With Achondroplasia
NCT07301463Achondroplasia
Abbisko Therapeutics Co, Ltd
Observational
260
Beijing, Guangzhou, Zhengzhou, Wuhan, Shanghai, Chengdu, Hangzhou
2025-06-20
Not yet open
Ji Yongling
Observational
34
Hangzhou
2025-06-16
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
25
Hangzhou
2025-06-15
Recruiting
Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
NCT06892145Systemic Lupus Erythematosus (SLE), Refractory
DrugMC-1-50
Chongqing Precision Biotech Co., Ltd
Phase 1
12
Hefei, Hangzhou
2025-06-12
Recruiting
Feasibility and Safety of Supraglottic Oxygen Delivery Via an Endotracheal Tube for Non-intubated ERCP Anesthesia: A Two-Stage Phase II Clinical Study
NCT07051980Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice, Pancreatitis, Cholelithiasis
Zhejiang University
Phase 2
50
Hangzhou
2025-06-12
Recruiting
Zhuhai Fapon Biopharma Co., Ltd.
Phase 1
108
Guangzhou, Wuhan, Nanchang, Taiyuan, Hangzhou
2025-06-12
Recruiting
COMBO Endoscopy Oropharyngeal Airway in Sedated Endoscopic Retrograde Cholangiopancreatography for Patients
NCT07012772Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice, Pancreatitis, Cholelithiasis
Zhejiang University
Phase 2
50
Hangzhou
2025-06-12
Recruiting
Akeso
Phase 3
999
Harbin, Shanghai, Hangzhou
2025-06-11
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
33
Hangzhou
2025-06-11
Recruiting
Zhejiang University
Phase 1
12
Hangzhou
2025-06-10
Recruiting
Protein Supplementation Intervention on Body Weight
NCT06989203Obesity, Weight Loss, Protein Supplementation
DrugSemaglutide
Chinese Academy of Sciences
Not applicable
140
Hangzhou
2025-06-10
Recruiting
Probiotic Intervention on Body Weight
NCT06989177Obesity, Homeostasis, Weight Loss, Probiotic Intervention
DrugSemaglutide
Chinese Academy of Sciences
Not applicable
140
Hangzhou
2025-06-10
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2025-06-09
Active, closed
Merck Sharp & Dohme LLC
Phase 2
149
Guangzhou, Changsha, Changchun, Shanghai, Ürümqi, Hangzhou
2025-06-09
Recruiting
Celgene
Phase 2
120
Hefei, Beijing, Wuhan, Nanjing, Shanghai Shi, Hangzhou
2025-06-09
Active, closed
A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
NCT06786338IgA Nephropathy (IgAN), C3 Glomerulopathy, IC-MPGN
DrugSGB-9768
Suzhou Sanegene Bio Inc.
Phase 2
45
Beijing, Changsha, Chengdu, Guiyang, Hangzhou, Shanghai, Yangzhou, Yinchuan
2025-06-06
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Observational
100
Hangzhou
2025-06-04
Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2
350
Hangzhou
2025-06-04
Recruiting
Study of ESG406 in Adults With Solid Tumors
NCT06979674Locally Advanced/Metastatic Solid Tumors
Shanghai Escugen Biotechnology Co., Ltd
Phase 1
556
Chongqing, Xi’an, Hangzhou
2025-06-04
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
10
Hangzhou
2025-06-04
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan
2025-06-04
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
1,624
Guangzhou, Shenzhen, Zhuhai, Xi’an, Hangzhou
2025-06-03
Recruiting
Omitting CTV for Primary Tumor in LS-SCLC
NCT07008716SCLC, Limited Stage, Radiation Exposure, Radiotherapy Side Effect, Progression
DrugsEtoposide·Cisplatin·Carboplatin
Sun Yat-sen University
Phase 3
852
Guangzhou, Hangzhou
2025-06-03
Recruiting
Minhu Chen
Observational
234
Guangzhou, Nanjing, Huangpu, Hangzhou
2025-06-03
Recruiting
Sanofi
Phase 2
99
Changsha, Changzhou, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang
2025-06-03
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
66
Hangzhou
2025-06-02
Active, closed
The R-E-V-I-V-A-L Study
NCT06992674Vestibular Migraine
DrugRimegepant
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
240
Hangzhou
2025-06-01
Recruiting
Romiplostim N01 for Platelet Recovery After Haploidentical HSCT
NCT07321626Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Delayed Platelet Engraftment, HSCT
DrugIpilimumab
First Affiliated Hospital of Zhejiang University
Phase 1
130
Hangzhou
2025-06-01
Recruiting
Sir Run Run Shaw Hospital
Not applicable
100
Hangzhou
2025-06-01
Recruiting
Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis
NCT06979271Telitacicept, Treatment Compliance, Rheumatoid Arthritis
Zhejiang Provincial People's Hospital
Observational
20
Hangzhou
2025-06-01
Recruiting
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
NCT07025174Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer, Cholangiocarcinoma
Drugs5-Fluorouracil/Leucovorin·Gemcitabine/Cisplatin·Anlotinib·Oxaliplatin
First Affiliated Hospital of Zhejiang University
Phase 2
60
Hangzhou
2025-06-01
Not yet open
Women's Hospital School Of Medicine Zhejiang University
Phase 3
200
Hangzhou
2025-06-01
Active, closed
Zhejiang University
Phase 2
24
Hangzhou
2025-06-01
Not yet open
Zhejiang Provincial People's Hospital
Observational
100
Hangzhou
2025-06-01
Not yet open
Auricular Acupressure for Perimenopausal Insomnia
NCT06856421Perimenopausal Insomnia
The First Affiliated Hospital of Zhejiang Chinese Medical University
Not applicable
160
Hangzhou
2025-06-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
5,000
Hangzhou, Shanghai
2025-06-01
Recruiting
Sir Run Run Shaw Hospital
Not applicable
140
Hangzhou
2025-06
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,244
Hangzhou
2025-05-31
Recruiting
Zhejiang Cancer Hospital
Observational
1,000,000
Hangzhou
2025-05-30
Not yet open
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
762
Hangzhou, Shanghai
2025-05-30
Recruiting
Hangzhou Converd Co., Ltd.
Phase 2
12
Hangzhou
2025-05-29
Recruiting
The Dental Hospital of Zhejiang University School of Medicine
Not applicable
160
Hangzhou
2025-05-27
Active, closed
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
NCT07035041UC - Ulcerative Colitis, Moderately to Severely Active Ulcerative Colitis
DrugD-2570
InventisBio Co., Ltd
Phase 2
120
Hangzhou
2025-05-22
By invitation
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
50
Hangzhou
2025-05-22
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
1,500
Hangzhou
2025-05-21
Not yet open
The First Affiliated Hospital of Zhejiang Chinese Medical University
Not applicable
90
Hangzhou
2025-05-20
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
160
Hangzhou
2025-05-20
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Guangzhou, Hangzhou, Hengyang, Nanning, Shenzhen, Taiyuan, Tianjin, Zhengzhou
2025-05-19
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Guangzhou, Shantou, Changsha, Changchun, Hangzhou, Beijing, Shanghai
2025-05-16
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
60
Hangzhou
2025-05-16
Recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
142
Hangzhou
2025-05-16
Recruiting
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
NCT06926283Prostate Cancer, Other Solid Tumors, Ewing Sarcoma
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
110
Changsha, Hangzhou, Beijing
2025-05-15
Not yet open
iCamuno Biotherapeutics Ltd.
Phase 1
12
Hangzhou
2025-05-15
Recruiting
Comparison of Sequential to Initial Combination Therapy in PAH
NCT06968962Pulmonary Arterial Hypertension (PAH)
DrugsAmbrisentan·Tadalafil
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
376
Hangzhou
2025-05-14
Recruiting
MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors
NCT06912152B7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid Tumors
Zhejiang University
Phase 1
12
Hangzhou
2025-05-12
Recruiting
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06801236Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited
Phase 1
88
Beijing, Hangzhou, Shanghai, Zhengzhou, Fuzhou
2025-05-12
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
18
Hangzhou
2025-05-09
Recruiting
Usynova Pharmaceuticals Ltd.
Phase 1
124
Hangzhou
2025-05-08
Not yet open
A Clinical Study of AK139 in Healthy Subjects
NCT06947109Healthy Subjects
Akeso
Phase 1
48
Hangzhou
2025-05-06
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
48
Hangzhou
2025-05-05
Recruiting
Effect of Video Viewing on Intravitreal Injection Experience
NCT07002372Age Related Macular Degeneration, Diabetic Retinopathy, Choroidal Neovascularization, Retinal Vein Occlusion
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
182
Hangzhou
2025-05-05
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
35
Hangzhou
2025-05-04
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
10
Hangzhou
2025-05-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
40
Hangzhou
2025-05-01
Not yet open
Zhejiang Cancer Hospital
Phase 2
58
Hangzhou
2025-05-01
Not yet open
Fecal Microbiota Transplantation for Preventing Gastrointestinal Symptoms in Extrapulmonary Neuroendocrine Neoplasms: A Real-World Study
NCT06924645Treatment-related Gastrointestinal Toxicity (Including Diarrhea, Constipation, Nausea, and Vomiting), Extrapulmonary Neuroendocrine Neoplasms
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
40
Hangzhou
2025-05-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
120
Hangzhou
2025-05-01
Not yet open
Qilu Pharmaceutical Co., Ltd.
Phase 1
256
Hangzhou
2025-05
Recruiting
Zhejiang Cancer Hospital
Phase 1/2
56
Hangzhou
2025-04-30
Recruiting
Shanghai Hutchison Pharmaceuticals Limited
Observational
4,500
Hangzhou
2025-04-30
Recruiting
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE
NCT06934447CAR T Cell Therapy, Systemic Lupus Erythematosus, BCMA
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
18
Hangzhou
2025-04-25
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2
120
Harbin, Hangzhou
2025-04-24
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
28
Hangzhou
2025-04-22
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
3,596
Hangzhou, Jinhua
2025-04-22
Active, closed
Zhejiang Doer Biologics Co., Ltd.
Phase 2
110
Hangzhou, Changchun, Nanjing
2025-04-22
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
43
Hangzhou
2025-04-22
By invitation
Sir Run Run Shaw Hospital
Not applicable
724
Hangzhou
2025-04-22
Recruiting
SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
NCT06850103Colorectal Carcinoma, Oligometastases, pMMR, MSS
DrugsCAPEOX/XELOX·Serplulimab
First Affiliated Hospital of Zhejiang University
Phase 2
51
Hangzhou
2025-04-22
Not yet open
Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study
NCT06922916COPD, Interstitial Pneumonia, Bronchiectasis, Respiratory Failure
Zhejiang University
Observational
250
Hangzhou
2025-04-22
Recruiting
Optimising TREATment for Severe Gram-Negative Bacterial Infections
NCT07004049Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Carbapenem Resistant Bacterial Infection
DrugsCeftolozane-tazobactam·Cefiderocol·Fosfomycin·Meropenem-Vaborbactam
National University of Singapore
Phase 4
600
Hangzhou, Xi'an, Xuzhou
2025-04-21
By invitation
VISOR Versus PCNL for Treatment of 2-4cm Renal Stones
NCT07159503Kidney Calculi, Kidney Stones
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
170
Hangzhou
2025-04-20
Recruiting
Zhejiang University
Phase 2
64
Hangzhou
2025-04-18
Active, closed
Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
Observational
1,000
Hangzhou
2025-04-17
Active, closed
Bisirna Therapeutics Pte. Ltd.
Phase 1
50
Beijing, Hangzhou
2025-04-15
Not yet open
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
260
Hangzhou
2025-04-15
Recruiting
Yi Liang
Not applicable
180
Hangzhou
2025-04-13
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
68
Hangzhou
2025-04-12
Recruiting
Pengfei Qiu
Not applicable
90
Hangzhou
2025-04-11
Recruiting
Zhejiang Provincial People's Hospital
Phase 4
268
Hangzhou
2025-04-11
Active, closed
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
NCT06866574Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Penile/Perianal/Perineal Cancer, Anal Cancer
Xiamen University
Phase 3
9,300
Fuzhou, Chengdu, Kunming, Hangzhou
2025-04-11
Recruiting
Zhejiang University
Not applicable
580
Hangzhou
2025-04-11
Recruiting
Effect of Ciprofol on Intraoperative Hypotension in Elderly Patients Receiving Renin-angiotensin System Inhibitors
NCT06952608Intraoperative Hypotension, Ciprofol, Renin-angiotensin System Inhibitors
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
140
Hangzhou
2025-04-10
Recruiting
Silkworm Pupa Powder Improves Dementia.
NCT06898476Alzheimer Disease(AD), Sarcopenia, Asthenia
Zhejiang Provincial Tongde Hospital
Not applicable
300
Hangzhou
2025-04-10
Recruiting
Zhejiang University
Phase 1/2
30
Hangzhou
2025-04-09
Recruiting
Zhejiang University
Phase 1/2
30
Hangzhou
2025-04-09
Recruiting
Hoffmann-La Roche
Phase 3
450
Xiangyang, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jiangmen
2025-04-09
Recruiting
Zhejiang University
Early Phase 1
18
Hangzhou
2025-04-08
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
18
Hangzhou
2025-04-08
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
72
Hangzhou
2025-04-07
Recruiting
Gilead Sciences
Phase 3
695
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-04-04
Recruiting
FBD Biologics Limited
Phase 1
50
Hangzhou, Xuzhou, Yantai, Zhujiang
2025-04-02
Recruiting
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
NCT06346600Neovascular (Wet) Age-related Macular Degeneration
Skyline Therapeutics
Observational
83
Hefei, Hangzhou, Wenzhou, Beijing, Shanghai
2025-04-02
Not yet open
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
NCT06888648Pancreatic Cancer Metastatic, Pancreatic Cancer Non-resectable
DrugSintilimab
Zhejiang University
Phase 1/2
30
Hangzhou
2025-04-01
Not yet open
Zhejiang University
Phase 1/2
60
Hangzhou
2025-04-01
Recruiting
Sir Run Run Shaw Hospital
Phase 2
70
Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou, Wenzhou
2025-04-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
302
Hangzhou
2025-04-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
38
Hangzhou
2025-04-01
Active, closed
Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer
NCT06992024Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
25
Hangzhou
2025-04-01
Not yet open
Sir Run Run Shaw Hospital
Phase 2
33
Hangzhou
2025-04-01
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Wuhan
2025-04-01
Not yet open
Zhejiang Cancer Hospital
Phase 2
42
Hangzhou
2025-04
Not yet open
Zhejiang University
Early Phase 1
18
Hangzhou
2025-04
Recruiting
Zhejiang Provincial People's Hospital
Phase 2
20
Hangzhou
2025-04
Not yet open
He Huang
Not applicable
24
Hangzhou
2025-03-31
Active, closed
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 2/3
1,003
Beijing, Changzhou, Chengdu, Guangzhou, Guangzhusi, Guizhou, Hangzhou, Harbin
2025-03-31
Recruiting
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Observational
683
Hangzhou
2025-03-31
Not yet open
Yi Liang
Observational
120
Hangzhou
2025-03-30
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
80
Hangzhou
2025-03-30
Recruiting
Daiichi Sankyo
Phase 3
510
Anyang, Beijing, Changchun, Changzhou, Chengdu, Fuzhou, Hangzhou, Harbin
2025-03-27
Active, closed
Fuming He
Observational
40
Hangzhou
2025-03-26
Recruiting
Hangzhou Medical College
Not applicable
76
Hangzhou
2025-03-26
Recruiting
Zhejiang University
Phase 2
133
Hangzhou
2025-03-25
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 3
194
Hangzhou, Harbin, Hefei, Jinhua, Nanchang, Nantong, Shanghai, Ürümqi
2025-03-24
Recruiting
Bayer
Phase 1/2
450
Beijing, Wuhan, Nanjing, Hangzhou
2025-03-21
Recruiting
QL1706 Combined With SOX Used in Theperioperative Treatment
NCT06766305Gastric Cancers, Esophagogastric Junction Cancers
DrugLenvatinib
Xiangdong Cheng
Phase 1/2
54
Hangzhou
2025-03-21
Active, closed
Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia
NCT06686485Concomitant Procedures, Atrial Fibrillation, PFA, LAAC
Boston Scientific Corporation
Observational
433
Suzhou, Beijing, Chengdu, Guangzhou, Guiyang, Hangzhou, Jinan, Kunming
2025-03-18
Recruiting
Hoffmann-La Roche
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-03-17
Recruiting
Kind Pharmaceuticals LLC
Phase 2
63
Hangzhou
2025-03-14
Recruiting
Bristol-Myers Squibb
Phase 3
60
Beijing, Chongqing, Guangzhou, Nanjing, Changchun, Hangzhou, Shanghai
2025-03-13
Recruiting
The Dental Hospital of Zhejiang University School of Medicine
Not applicable
40
Wuhan, Hangzhou, Shanghai
2025-03-12
By invitation
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Phase 3
460
Hangzhou
2025-03-12
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
51
Hangzhou, Dongyang, Huzhou, Jiaxing, Lishui, Ningbo, Quzhou, Shaoxing
2025-03-11
Recruiting
Drug-induced Kidney Injury Model
NCT06939387Acute Kidney Injury
Zhejiang Provincial People's Hospital
Observational
1,500
Hangzhou
2025-03-10
Recruiting
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
NCT07167160Cervical Cancer, Immunochemotherapy
DrugCamrelizumab
Women's Hospital School Of Medicine Zhejiang University
Phase 2
59
Hangzhou
2025-03-10
Recruiting
A Study to Evaluate the Safety, Tolerability and PK of SK-08
NCT07021157Chronic Kidney Disease(CKD)
Consun Pharmaceutical Group
Phase 1
48
Hangzhou
2025-03-09
Not yet open
LiChaoran
Not applicable
80
Hangzhou
2025-03-05
Recruiting
First People's Hospital of Hangzhou
Not applicable
100
Hangzhou
2025-03-04
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
30
Hangzhou
2025-03-04
Active, closed
Blended Cardiac Rehabilitation Training for Cardiology Residents
NCT07755878Medical Education, Cardiac Rehabilitation
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
98
Hangzhou
2025-03-03
By invitation
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
42
Hangzhou
2025-03-01
Not yet open
First Affiliated Hospital of Zhejiang University
Phase 2
23
Hangzhou
2025-03-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
450
Hangzhou, Shanghai
2025-03-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
390
Hangzhou
2025-03-01
Not yet open
Guangzhou Jiayin Biotech Ltd
Phase 1/2
16
Nanjing, Hangzhou
2025-03-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2025-03-01
Recruiting
Epidural Electrical Stimulation in Spinal Cord Injury
NCT07105878Spinal Cord Injuries (SCI)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
10
Hangzhou
2025-03-01
Active, closed
Yijun Luo
Observational
160
Hangzhou
2025-03-01
Recruiting
Li Lab,MD
Phase 2
100
Hangzhou
2025-03-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
48
Hangzhou
2025-03-01
Not yet open
Zhejiang University
Phase 2
20
Hangzhou
2025-03-01
Recruiting
Zhejiang Cancer Hospital
Phase 1/2
10
Hangzhou
2025-03-01
Not yet open
He Huang
Not applicable
24
Hangzhou
2025-03
Recruiting
Zhejiang Provincial People's Hospital
Not applicable
160
Hangzhou
2025-02-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
327
Beijing, Fuzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2025-02-27
Recruiting
Daiichi Sankyo
Phase 3
726
Beijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou
2025-02-27
Recruiting
Daiichi Sankyo
Observational
260
Beijing, Changchun, Changzhi, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2025-02-27
Recruiting
Qurgen Inc.
Phase 1
96
Beijing, Lanzhou, Guangzhou, Nanjing, Xi'an, Jinan, Shanghai, Hangzhou
2025-02-26
Recruiting
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Not yet open
Zhejiang Provincial People's Hospital
Phase 1/2
30
Hangzhou
2025-02-22
Recruiting
Daiichi Sankyo
Observational
150
Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei
2025-02-21
Recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
20
Hangzhou
2025-02-20
Not yet open
Zhejiang Provincial People's Hospital
Not applicable
300
Hangzhou
2025-02-20
Active, closed
Gilead Sciences
Phase 2
39
Chengdu, Hangzhou, Nanning, Shanghai, Wuhan
2025-02-18
Recruiting
First People's Hospital of Hangzhou
Phase 2/3
240
Hangzhou
2025-02-17
Recruiting
Zhejiang Cancer Hospital
Not applicable
44
Hangzhou
2025-02-14
Recruiting
Women's Hospital School Of Medicine Zhejiang University
Observational
1,000,000
Hangzhou
2025-02-14
Recruiting
Bayer
Phase 2
111
Beijing, Changsha, Shanghai, Hangzhou
2025-02-13
Recruiting
Remimazolam Besylate in Sedation of Postcardioperative Patients
NCT06716840Remimazolam, Propofol, Sedation, Mechanical Ventilation
DrugsRemimazolam·Propofol
First Affiliated Hospital of Zhejiang University
Not applicable
120
Hangzhou
2025-02-10
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
41
Hangzhou
2025-02-10
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
300
Hangzhou
2025-02-10
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
60
Hangzhou
2025-02-10
Not yet open
First Affiliated Hospital of Zhejiang University
Early Phase 1
18
Hangzhou
2025-02-10
By invitation
Correlation Between CEUS Identification of Nodular HPD on CE-MRI and Hepatic Malignant Lesions
NCT06816212Hepatic Malignant Tumors, Hepatic Perfusion Disorders
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
280
Hangzhou
2025-02-10
Not yet open
Clinical Classification of MAFLD Based Liver Biopsy
NCT06795646Metabolic Dysfunction Associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis (MASH)
Beijing Friendship Hospital
Observational
2,000
Beijing, Hangzhou, Shanghai, Tianjin
2025-02-08
Active, closed
Sanofi
Phase 3
216
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Jinan, Jingzhou, Nanning
2025-02-06
Recruiting
LEO Pharma
Phase 3
90
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Shanghai, Shenzhen
2025-02-05
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
114
Hangzhou
2025-02-05
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
200
Hangzhou
2025-02-04
Recruiting
BeOne Medicines
Phase 1
120
Guangzhou, Zhengzhou, Shanghai, Tianjin, Hangzhou
2025-02-04
Recruiting
BioNTech SE
Phase 3
621
Changchun, Baoding, Beijing, Bengbu, Fuzhou, Guangzhou, Hangzhou, Ha’erbin
2025-02-03
Recruiting
Zhejiang Cancer Hospital
Observational
200
Hangzhou
2025-02-01
Recruiting
Zhejiang Cancer Hospital
Phase 2
30
Hangzhou
2025-02-01
Recruiting
Beijing Chao Yang Hospital
Not applicable
200
Beijing, Guangzhou, Zhengzhou, Changsha, Shenyang, Shanghai, Taiyuan, Hangzhou
2025-02-01
Recruiting
Sinocelltech Ltd.
Phase 1/2
168
Beijing, Changchun, Guangzhou, Hangzhou, Jiujiang, Kunming, Linfen, Mianyang
2025-02
Recruiting
He Huang
Early Phase 1
9
Hangzhou
2025-01-31
Recruiting
Zhejiang University
Early Phase 1
20
Hangzhou
2025-01-31
Recruiting
Zhejiang University
Early Phase 1
15
Hangzhou
2025-01-31
Not yet open
A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.
NCT06766552Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Nr-axSpA, Polymyalgia Rheumatica (PMR)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Hangzhou
2025-01-30
Recruiting
Zhejiang University
Early Phase 1
20
Hangzhou
2025-01-30
Recruiting
Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
NCT06792799Autoimmune Diseases, Systemic Lupus Erthematosus, Multi-Drug Resistant Nephrotic Syndrome, IgAN - IgA Nephropathy
The Children's Hospital of Zhejiang University School of Medicine
Early Phase 1
36
Hangzhou
2025-01-30
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou
2025-01-29
Recruiting
Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University
Observational
200
Hangzhou
2025-01-28
Recruiting
Intravenous Thrombolysis and NOAC
NCT06749834Acute Ischemic Stroke
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
280
Hangzhou, Taizhou
2025-01-27
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
2,804
Hangzhou
2025-01-27
Recruiting
Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease
NCT07872423Anti IL-6R, Castleman's Disease, Multicentric
Beijing VDJBio Co., LTD.
Phase 3
45
Beijing, Xiamen, Wuhan, Nanjing, Nanchang, Taiyuan, Chengdu, Hangzhou
2025-01-27
Active, closed
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 2
24
Tianjin, Hangzhou
2025-01-23
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
160
Hangzhou
2025-01-20
Not yet open
Zhejiang University
Phase 2
43
Hangzhou
2025-01-15
By invitation
Genecombio Ltd.
Not applicable
6
Hangzhou
2025-01-15
Not yet open
Zhejiang University
Early Phase 1
6
Hangzhou
2025-01-10
Recruiting
Zhejiang University
Early Phase 1
27
Hangzhou
2025-01-10
Recruiting
Zhejiang University
Phase 1
12
Hangzhou
2025-01-10
Recruiting
BioNTech SE
Phase 2/3
1,580
Baoding, Beijing, Bengbu, Changchun, Changsha, Hangzhou, Jiamusi, Jinan
2025-01-07
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
38
Yangzhou, Shanghai, Hangzhou, Huzhou, Jiaxing, Ningbo, Wenzhou
2025-01-06
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
116
Hangzhou
2025-01-06
Recruiting
Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
NCT06614270Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM), Sjogren's Syndrome
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
15
Hangzhou
2025-01-06
Recruiting
Personalized DBS Targeting for Treating Depression
NCT06784388Treatment-resistant Depression (TRD)
DrugEsketamine
Second Affiliated Hospital, Zhejiang University, School of Medicine
Early Phase 1
5
Hangzhou
2025-01-05
Recruiting
The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion
NCT06012760Anemia, Iron Deficiency Anemia, Perioperative, Transfusion
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
400
Hangzhou
2025-01-04
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2025-01-03
Not yet open
Yanbu Ke
Not applicable
100
Hangzhou
2025-01-02
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
60
Hangzhou
2025-01-01
Recruiting
AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy
NCT07263204Hypertrophic Cardiomyopathy (HCM), Left Ventricular Hypertrophy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
15,000
Hangzhou
2025-01-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
394
Hangzhou, Shaoxing
2025-01-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
200
Hangzhou
2025-01-01
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
300
Hangzhou
2025-01-01
Not yet open
Sinocelltech Ltd.
Phase 1/2
99
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning
2025-01
Not yet open
Zhejiang Cancer Hospital
Phase 2
58
Hangzhou
2024-12-31
Not yet open
Tasly Pharmaceutical Group Co., Ltd
Phase 3
520
Baoding, Beijing, Changsha, Chengde, Chengdu, Guangzhou, Hangzhou, Kaifeng
2024-12-30
Not yet open
Yi Liang
Observational
400
Hangzhou
2024-12-30
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
190
Hefei, Fuzhou, Zhengzhou, Changsha, Nanchang, Jinan, Hangzhou
2024-12-30
Recruiting
Liposomal Irinotecan and Apatinib in ES-SCLC
NCT06749691Small Cell Lung Cancer Extensive Stage
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
30
Hangzhou
2024-12-28
Not yet open
Zhejiang University
Observational
20
Hangzhou
2024-12-28
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
74
Hangzhou
2024-12-26
Recruiting
CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
NCT06937567Biliary Tract Cancer, Colorectal Carcinoma, Gastric Cancer, Metastatic, Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
Zhejiang University
Early Phase 1
36
Hangzhou
2024-12-26
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
10
Hangzhou
2024-12-26
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
96
Hangzhou
2024-12-25
Recruiting
An Exploratory Study on Gene Methylation Detection of Colorectal Cancer
NCT07033156CRC (Colorectal Cancer), Adenoma Colon
Zhejiang Provincial People's Hospital
Observational
450
Hangzhou
2024-12-24
Recruiting
Zhejiang University
Early Phase 1
36
Hangzhou
2024-12-24
Recruiting
Ractigen Therapeutics.
Phase 1
32
Beijing, Chengdu, Hangzhou
2024-12-24
Active, closed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1
12
Beijing, Guangzhou, Hangzhou
2024-12-20
Recruiting
Weiliang Shen, Ph.D., M.D.
Phase 2/3
20
Hangzhou
2024-12-19
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
102
Hangzhou
2024-12-16
Recruiting
Suzhou Biomissile Pharmaceuticals Co., Ltd.
Phase 1
123
Bengbu, Shanghai, Hangzhou
2024-12-16
Recruiting
GlaxoSmithKline
Phase 3
520
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai
2024-12-16
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
60
Hangzhou
2024-12-15
Recruiting
Universal CNK-UT Therapy for Refractory aGVHD
NCT06750133Acute Graft-versus-Host Disease
First Affiliated Hospital of Zhejiang University
Phase 1
23
Fuzhou, Hangzhou
2024-12-14
Active, closed
AbbVie
Phase 2
185
Beijing, Langfang, Harbin, Wuhan, Hangzhou
2024-12-13
Active, closed
Ausper Biopharma Co., Ltd.
Phase 2
105
Chongqing, Fuzhou, Guangzhou, Changzhou, Zhenjiang, Hangzhou
2024-12-13
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Changsha, Chengdu, Ganzhou, Guangzhou, Hangzhou, Harbin
2024-12-12
Recruiting
GlaxoSmithKline
Phase 3
514
Beijing, Chengdu, Hangzhou, Mianyang, Shanghai, Shenyang, Zhuzhou
2024-12-12
Recruiting
Basilea Pharmaceutica
Phase 3
450
Beijing, Bengbu, Chengdu, Guangzhou, Hangzhou, Lishui, Liuzhou, Nanchang
2024-12-11
Active, closed
Hoffmann-La Roche
Phase 3
350
Beijing, Kunming, Changsha, Chengdu, Guangzhou, Hangzhou, Huizhou, Nanning
2024-12-11
Recruiting
Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus
NCT06789107Systemic Lupus Erythematosus (SLE), Children, Blinatumomab
DrugBlinatumomab
Mao Jianhua
Phase 1
6
Hangzhou
2024-12-08
Recruiting
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
NCT06832904HER2-positive Breast Cancer, Neoadjuvant Therapy, Pyrotinib
First Affiliated Hospital of Zhejiang University
Phase 2
33
Hangzhou
2024-12-03
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
24
Hangzhou
2024-12-01
Recruiting
Zhejiang University
Early Phase 1
36
Hangzhou
2024-12-01
By invitation
Risk Model for Metastasis Detection of Neuroblastoma
NCT06703944Neuroblastoma (NB), Prognosis, Bone Marrow Metastasis, Bone Metastases
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
500
Shanghai, Hangzhou, Shenzhen
2024-12-01
Recruiting
The Application of Eye-Tracking Technology in Perioperative Management and Education
NCT06766539Eye-tracking Technology, Medical Education, Perioperative Management, Attention Distribution
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
300
Hangzhou
2024-12-01
Recruiting
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
NCT06696846Relapsed/Refractory T-cell Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
25
Hangzhou
2024-12-01
Recruiting
YiLin Zhao
Observational
45
Hefei, Hangzhou
2024-12-01
Recruiting
First Affiliated Hospital of Zhejiang University
Observational
45
Hangzhou
2024-12-01
Recruiting
VHAG in Treating R/R T-ALL/LBL
NCT06742463Acute T Lymphpblastic Leukemia/Lymphoma
DrugsHomoharringtonine·G-Csf·Ara-C·Cytarabine
First Affiliated Hospital of Zhejiang University
Phase 2
50
Hangzhou
2024-12
Not yet open
Predicting Treatment Failure in HSIL Patients with Positive Margins After Conization Via Detection of PAX1 Methylation
NCT06713655High-grade Squamous Intraepithelial Lesions (HSIL), Cervical Conization
Women's Hospital School Of Medicine Zhejiang University
Observational
800
Hangzhou
2024-12
Not yet open
Zhejiang Provincial People's Hospital
Not applicable
220
Hangzhou
2024-12
Recruiting
The Third Affiliated hospital of Zhejiang Chinese Medical University
Phase 4
144
Hangzhou
2024-12
Rows per page Showing 501–1000 of 1819
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,819 of those studies with a site in Hangzhou.

How many clinical trials are recruiting in Hangzhou?

1,098 of the 1,819 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 309 have not yet opened recruitment, 370 are active but closed to new participants, and 42 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.